HTB 13 December 2019 online
13 December 2019. Related: Editorial.
This final edition of HTB continues our reports from the 17th EACS conference recently held in Basel.
These include early data on a long acting (6-monthly) capsid inhibitor for MDR HIV, a review of dual therapy with dolutegravir/lamivudine, the lack of weight gain with doravirine, and an analysis on bone and renal changes in the ADVANCE study.
We also include a report on HIV loneliness from the recent workshop on HIV and Ageing.
ARV news includes: new UK access to doravirine, FDA submission for fostemsavir (but now on named patent access) and submission of a new paediatric formulation of dolutegravir.
Over the last few months i-Base has updated three treatment guides – see below – and we proudly distribute these free.
However, any loose change you have during the holiday season could find a worse home that the i-Base appeal.
Thank you to all our supporters who have contributed…